The American Pharmacists Association (APhA) has launched new and current training programs and resources to assist responders on the front lines of health care in staying safe and up to date with the latest research and practice guidance for the COVID-19 pandemic, it was reported on Tuesday.
APhA vice president, Professional Education Resources, Daniel Zlott, PharmD, BCOP, said, 'We are diligently working on behalf of pharmacists and patients to address the training needs of all as we face unprecedented times. Pharmacists can assist patients in a number of ways, including helping to increase the number of individuals who are able to be tested for COVID-19 and providing education to patients.'
The APhA's COVID-19 Specimen Collection Training guides pharmacists through the collection of nasopharyngeal swabs. The program will be adaptable to other testing methods once they become more widely available, such as nasal swabs, oral swabs, fingerstick tests, and other new technologies.
Dexcom highlights new diabetes outcomes and product roadmap at ATTD 2026
Curatis and Neupharma partner to develop corticorelin for peritumoral brain edema in Japan
Samsung Biologics collaborates with Lilly for new Gateway Labs site in Korea
Citius Oncology reports positive topline results from Phase 1 clinical trial of LYMPHIR combination
GenomOncology partners with WeTrials to support CNS cancer clinical trials
Target ALS awards two-year research grant to AcuraStem for advancing therapeutics targeting SYF2
Ascletis reports Phase II weight‑loss results for ASC30 depot formulation
NS Pharma and NCNP report 4.5-year brogidirsen data for DMD treatment
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
Koselugo approved in Canada for adults with NF1 and inoperable plexiform neurofibromas
Bristol Myers Squibb reports positive Phase 3 results for oral mezigdomide in multiple myeloma
Pfizer reports positive Phase 2 results for trispecific antibody in atopic dermatitis
Agilent to acquire Biocare Medical for USD950m to expand pathology portfolio